Last reviewed · How we verify

MM120 (LSD D-Tartrate) — Competitive Intelligence Brief

MM120 (LSD D-Tartrate) (MM120 (LSD D-Tartrate)) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Serotonergic psychedelic / 5-HT agonist. Area: Psychiatry / Mental Health.

phase 3 Serotonergic psychedelic / 5-HT agonist 5-HT1A, 5-HT2A, 5-HT7 receptors Psychiatry / Mental Health Small molecule Live · refreshed every 30 min

Target snapshot

MM120 (LSD D-Tartrate) (MM120 (LSD D-Tartrate)) — Definium Therapeutics US, Inc.. MM120 is a formulated version of LSD (lysergic acid diethylamide) that acts as a serotonin 5-HT receptor agonist, particularly at 5-HT1A and 5-HT2A receptors, to modulate neural circuits involved in mood and perception.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
MM120 (LSD D-Tartrate) TARGET MM120 (LSD D-Tartrate) Definium Therapeutics US, Inc. phase 3 Serotonergic psychedelic / 5-HT agonist 5-HT1A, 5-HT2A, 5-HT7 receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Serotonergic psychedelic / 5-HT agonist class)

  1. Definium Therapeutics US, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). MM120 (LSD D-Tartrate) — Competitive Intelligence Brief. https://druglandscape.com/ci/mm120-lsd-d-tartrate. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: